Jorge R Miranda-Massari

Dr. Jorge R Miranda-Massari

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2021 in Life
Verified
Journal Article
Open access
PDF file
Jorge R Miranda-MassariJorge R Miranda-Massari
Jorge R Miranda-Massari
ATAlondra P. Toro
Alondra P. Toro
Doris LohDoris Loh
Doris Loh
JRJose R. Rodriguez
Jose R. Rodriguez
RMRaul H Morales-Borges
Raul H Morales-Borges
Michael J GonzalezMichael J Gonzalez
Michael J Gonzalez
Currently available anti-viral drugs may be useful in reducing the viral load but are not providing the necessary physiological effects to reduce the SARS-CoV-2 complications efficiently. Treatments that provide better clinical outcomes are urgently needed. Vitamin C (ascorbic acid, AA) is an essential nutrient with many biological roles that have been proven to play an important part in immune function; it serves as an antioxidant, an anti-viral, and exerts anti-thrombotic effects among many other physiological benefits. Research has proven that AA at pharmacological doses can be beneficial to patients with acute respiratory distress syndrome (ARDS) and other respiratory illnesses, including sepsis. In addition, High-Dose Intravenous Vitamin C (HDIVC) has proven to be effective in patients with different viral diseases, such as influenza, chikungunya, Zika, and dengue. Moreover, HDIVC has been demonstrated to be very safe. Regarding COVID-19, vitamin C can suppress the cytokine storm, reduce thrombotic complications, and diminish alveolar and vascular damage, among other benefits. Due to these reasons, the use of HDIVC should be seriously considered in complicated COVID-19 patients. In this article, we will emphasize vitamin C’s multiple roles in the most prominent pathophysiological processes presented by the COVID-19 disease.

4 March 2011 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
TIThomas Ichim
Thomas Ichim
Boris MinevBoris Minev
Boris Minev
TBTodd Braciak
Todd Braciak
BLBrandon Luna
Brandon Luna
RHRon Hunninghake
Ron Hunninghake
NRNeil H Riordan
Neil H Riordan
The history of ascorbic acid (AA) and cancer has been marked with controversy. Clinical studies evaluating AA in cancer outcome continue to the present day. However, the wealth of data suggesting that AA may be highly beneficial in addressing cancer-associated inflammation, particularly progression to systemic inflammatory response syndrome (SIRS) and multi organ failure (MOF), has been largely overlooked. Patients with advanced cancer are generally deficient in AA. Once these patients develop septic symptoms, a further decrease in ascorbic acid levels occurs. Given the known role of ascorbate in: a) maintaining endothelial and suppression of inflammatory markers; b) protection from sepsis in animal models; and c) direct antineoplastic effects, we propose the use of ascorbate as an adjuvant to existing modalities in the treatment and prevention of cancer-associated sepsis.

1 June 2007 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
Jorge DucongeJorge Duconge
Jorge Duconge
Jorge R Miranda-MassariJorge R Miranda-Massari
Jorge R Miranda-Massari
MGMichael J González
Michael J González
PTPaul R Taylor
Paul R Taylor
HRHugh D Riordan
Hugh D Riordan
KAKevin Alliston
Kevin Alliston

19 September 2014
Verified
Book Chapter
Closed access
PDF file
MGMichael J. Gonzalez
Michael J. Gonzalez
Jorge R Miranda-MassariJorge R Miranda-Massari
Jorge R Miranda-Massari

19 November 2019 in Journal of Restorative Medicine
Verified
Journal Article
Open access
PDF file
Jorge R Miranda-MassariJorge R Miranda-Massari
Jorge R Miranda-Massari
IAInés Alfaro
Inés Alfaro

1 January 2023 in Journal of Restorative Medicine
Verified
Journal Article
Open access
PDF file
Jorge R Miranda-MassariJorge R Miranda-Massari
Jorge R Miranda-Massari
MGMichael Gonzalez
Michael Gonzalez
JRJose Rodriguez-Gomez
Jose Rodriguez-Gomez
We propose the concept of the net micronutrient balance value (NMBV), which refers to the actual micronutrient content of the food product minus the portion not absorbed and the amount depleted in metabolic processes due to additives, contaminants, medication, and faulty metabolism.